Treatment of adult patients with schizophrenia and complex mental health needs: A national clinical guideline
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Treatment of adult patients with schizophrenia and complex mental health needs : A national clinical guideline. / Baandrup, Lone; Østrup Rasmussen, Jesper; Klokker, Louise; Austin, Stephen; Bjørnshave, Thomas; Fuglsang Bliksted, Vibeke; Fink-Jensen, Anders; Hedegaard Fohlmann, Allan; Peter Hansen, Jens; Kristine Nielsen, Malene; Sandsten, Karl Erik; Schultz, Vilhelm; Voss-Knude, Susanne; Nordentoft, Merete.
I: Nordic Journal of Psychiatry, Bind 70, Nr. 3, 2016, s. 231-40.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Treatment of adult patients with schizophrenia and complex mental health needs
T2 - A national clinical guideline
AU - Baandrup, Lone
AU - Østrup Rasmussen, Jesper
AU - Klokker, Louise
AU - Austin, Stephen
AU - Bjørnshave, Thomas
AU - Fuglsang Bliksted, Vibeke
AU - Fink-Jensen, Anders
AU - Hedegaard Fohlmann, Allan
AU - Peter Hansen, Jens
AU - Kristine Nielsen, Malene
AU - Sandsten, Karl Erik
AU - Schultz, Vilhelm
AU - Voss-Knude, Susanne
AU - Nordentoft, Merete
PY - 2016
Y1 - 2016
N2 - BACKGROUND AND AIM: The Danish Health and Medicines Authority assembled a group of experts to develop a national clinical guideline for patients with schizophrenia and complex mental health needs. Within this context, ten explicit review questions were formulated, covering several identified key issues.METHODS: Systematic literature searches were performed stepwise for each review question to identify relevant guidelines, systematic reviews/meta-analyses, and randomized controlled trials. The quality of the body of evidence for each review question was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Clinical recommendations were developed on the basis of the evidence, assessment of the risk-benefit ratio, and perceived patient preferences.RESULTS: Based on the identified evidence, a guideline development group (GDG) recommended that the following interventions should be offered routinely: antipsychotic maintenance therapy, family intervention and assertive community treatment. The following interventions should be considered: long-acting injectable antipsychotics, neurocognitive training, social cognitive training, cognitive behavioural therapy for persistent positive and/or negative symptoms, and the combination of cognitive behavioural therapy and motivational interviewing for cannabis and/or central stimulant abuse. SSRI or SNRI add-on treatment for persistent negative symptoms should be used only cautiously. Where no evidence was available, the GDG agreed on a good practice recommendation.CONCLUSIONS: The implementation of this guideline in daily clinical practice can facilitate good treatment outcomes within the population of patients with schizophrenia and complex mental health needs. The guideline does not cover all available interventions and should be used in conjunction with other relevant guidelines.
AB - BACKGROUND AND AIM: The Danish Health and Medicines Authority assembled a group of experts to develop a national clinical guideline for patients with schizophrenia and complex mental health needs. Within this context, ten explicit review questions were formulated, covering several identified key issues.METHODS: Systematic literature searches were performed stepwise for each review question to identify relevant guidelines, systematic reviews/meta-analyses, and randomized controlled trials. The quality of the body of evidence for each review question was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. Clinical recommendations were developed on the basis of the evidence, assessment of the risk-benefit ratio, and perceived patient preferences.RESULTS: Based on the identified evidence, a guideline development group (GDG) recommended that the following interventions should be offered routinely: antipsychotic maintenance therapy, family intervention and assertive community treatment. The following interventions should be considered: long-acting injectable antipsychotics, neurocognitive training, social cognitive training, cognitive behavioural therapy for persistent positive and/or negative symptoms, and the combination of cognitive behavioural therapy and motivational interviewing for cannabis and/or central stimulant abuse. SSRI or SNRI add-on treatment for persistent negative symptoms should be used only cautiously. Where no evidence was available, the GDG agreed on a good practice recommendation.CONCLUSIONS: The implementation of this guideline in daily clinical practice can facilitate good treatment outcomes within the population of patients with schizophrenia and complex mental health needs. The guideline does not cover all available interventions and should be used in conjunction with other relevant guidelines.
KW - Journal Article
KW - Research Support, Non-U.S. Gov't
U2 - 10.3109/08039488.2015.1074285
DO - 10.3109/08039488.2015.1074285
M3 - Review
C2 - 26328910
VL - 70
SP - 231
EP - 240
JO - Nordisk Psykiatrisk Tidsskrift
JF - Nordisk Psykiatrisk Tidsskrift
SN - 0803-9496
IS - 3
ER -
ID: 164427730